 The purpose of this study was to estimate the response rate of ixabepilone monotherapy, and the combination of ixabepilone plus cetuximab as first-line treatment of female subjects with triple negative estrogen receptor ER, progesterone receptor PR, Human Epidermal Growth Factor Receptor 2 HER2 negative locally advanced non-resectable andor metastatic breast cancer 